Krane Funds Advisors LLC Bei Gene, Ltd. Transaction History

Krane Funds Advisors LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$131.8 - $202.24 $527 - $808	4 Added 0.02%	21,861 $2.95 Million
Q2 2022 Aug 11, 2022	SELL	$121.11 - $216.05 $132,615 - $236,574	-1,095 Reduced 4.77%	21,857 $3.54 Million
Q1 2022 May 11, 2022	BUY	$146.52 - $269.56 $289,230 - $532,111	1,974 Added 9.41%	22,952 $4.33 Million
Q4 2021 Feb 10, 2022	SELL	$248.56 - $389.34 $1.02 Million - $1.6 Million	-4,107 Reduced 16.37%	20,978 $5.68 Million
Q3 2021 Nov 12, 2021	SELL	$249.6 - $403.14 $659,193 - $1.06 Million	-2,641 Reduced 9.53%	25,085 $9.11 Million
Q2 2021 Aug 12, 2021	SELL	$292.75 - $367.01 $35,422 - $44,408	-121 Reduced 0.43%	27,726 $9.52 Million
Q1 2021 May 14, 2021	BUY	$260.64 - $382.12 $1.86 Million - $2.73 Million	7,134 Added 34.44%	27,847 $9.69 Million
Q4 2020 Feb 11, 2021	BUY	$221.31 - $316.61 $4.58 Million - $6.56 Million	20,713 New	20,713 $5.35 Million
Q4 2018 Feb 14, 2019	SELL	$107.01 - $175.15 $24,826 - $40,634	-232 Closed	0 $0
Q3 2018 Nov 19, 2018	BUY	$152.62 - $189.66 $35,407 - $44,001	232 New	232 $40,000

250

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $19.8B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Krane Funds Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Krane Funds Advisors LLC with notifications on news.